Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tessa Romero
JPMorgan Chase & Co, Research Division

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I’m one of the senior biotech analysts here at JPMorgan. Our next presenting company is Nurix Therapeutics, and presenting on behalf of the company, we have President and CEO, Arthur Sands.

Arthur, over to you.

Arthur Sands
CEO, President & Director

Well, thank you, Tessa, and I’d like to thank the entire JPMorgan banking team for inviting us to this great conference. Another great year starting off here in 2026 jam-packed schedule. I will be making certain forward-looking statements. I refer you to our filings with the SEC.

So at Nurix, we’re dedicated to our mission to establish degrader-based mechanisms at the forefront of patient care. And this is an important emerging class that we see in the context here as shown on this slide, as a major new class of agents. And as agents have evolved over time, we’ve seen many new categories of therapeutics.

Of course, if you go way back, small molecule inhibitors on the left, the original drugs, really very little innovation has taken place in the area of small molecules, I’d say, in terms of modality until targeted protein degraders all the way on the right. And these are unique small molecule drugs.

I’ll describe some of the attributes that distinguish them and make them what we believe will be a category medicine at least as large as antibodies, share certain things in common with nucleic acid-based therapies in terms of knocking down targets